Healthcare Providers and Services
Company Overview of Genzyme Polyclonals S.A.S.
Genzyme Polyclonals S.A.S. operates as a subsidiary of Genzyme Corporation.
Les Carrés du Parc
10 rue des Rosiéristes - BP 54
Champagne au Mont D´Or
33 4 37 28 16 00
33 4 37 28 16 79
Key Executives for Genzyme Polyclonals S.A.S.
Chief Executive Officer and Chief Operating Officer
Compensation as of Fiscal Year 2014.
Genzyme Polyclonals S.A.S. Key Developments
Genzyme Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM
Mar 5 15
Genzyme Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France. Speakers: Robin Kenselaar, VP, Europe, Middle East, Africa.
Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders
Feb 11 15
Voyager Therapeutics, Inc. and Genzyme, a Sanofi company announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. The collaboration will leverage Genzyme's long-standing commitment and scientific leadership in the field of adeno-associated virus (AAV) gene therapy and Voyager's AAV product engine to develop breakthrough therapies for patients suffering from severe CNS disorders. The alliance will encompass multiple gene therapy programs, including programs for Parkinsonâ s disease, Friedreich's ataxia and Huntington's disease, as well as other CNS disorders. Each program targets a severe, debilitating disease and has the potential to deliver transformational therapeutic benefit for patients. The collaboration portfolio created will combine programs and intellectual property from both companies. Voyager will drive research and development activities for all programs, working with Genzyme in a highly collaborative way. Genzyme will have the option to license several programs following completion of an initial proof-of-concept human clinical trial. However, Voyager will retain all U.S. rights to its lead product programs in Parkinsonâ s disease (VY-AADC01) and Friedreich's ataxia (VY-FXN01). Voyager will split U.S. profits with Genzyme for the Huntingtonâ s disease program (VY-HTT01). In addition, Voyager's lead amyotrophic lateral sclerosis (ALS) program (VY-SOD101) is not part of the collaboration and Voyager retains worldwide rights to this program.
Genzyme and Isis Pharmaceuticals Inc. Present Kynamro Clinical Data at the American Heart Association
Nov 18 14
Genzyme and Isis Pharmaceuticals Inc. announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. This retrospective analysis included 104 patients who enrolled in the long-term extension study of KYNAMRO after having completed one of the KYNAMRO phase 3 blinded, randomized, placebo-controlled 6-month trials in patients with homozygous and heterozygous FH. All patients who completed at least two years of treatment with KYNAMRO were included in the analysis. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|